We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+22.19%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.06B
AUM Growth
+$94.9M
Cap. Flow
-$114M
Cap. Flow %
-5.52%
Top 10 Hldgs %
74.94%
Holding
37
New
2
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$43.1M
2
LOXO
Loxo Oncology, Inc
LOXO
+$20.9M
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$5.76M
4
TRVN
Trevena, Inc.
TRVN
+$5.3M
5
AGRX
Agile Therapeutics
AGRX
+$635K

Top Sells

Rank Stock Value
1
GRPN icon
Groupon
GRPN
+$72.3M
2
CVT
CVENT, INC.
CVT
+$52.3M
3
ARDX icon
Ardelyx
ARDX
+$23.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$22M
5
ALIM
Alimera Sciences
ALIM
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 52.78%
2 Communication Services 18.33%
3 Technology 12.38%
4 Consumer Discretionary 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$366M 17.77%
9,854,255
– –
GRPN icon
2
Groupon
GRPN
$1.07B
$365M 17.69%
2,208,648
-508,931
-19% -$72.3M
OPWR
3
DELISTED
OPOWER INC COM STK (DE)
OPWR
$128M 6.21%
8,997,290
– –
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$128M 6.19%
2,279,781
– –
RNA
5
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$122M 5.89%
6,480,171
– –
ARDX icon
6
Ardelyx
ARDX
$1.24B
$106M 5.15%
5,621,199
-1,000,000
-15% -$23.2M
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$97.2M 4.71%
5,149,740
– –
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.73B
$88.4M 4.29%
10,650,000
– –
CVT
9
DELISTED
CVENT, INC.
CVT
$83.4M 4.05%
2,996,738
-1,997,368
-40% -$52.3M
CBIO
10
Crescent Biopharma
CBIO
$570M
$61.7M 2.99%
85,751
– –
HPTX
11
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$57.2M 2.77%
2,384,221
– –
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$53M 2.57%
+1,369,899
New +$43.1M
TRIV
13
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$49.6M 2.4%
3,945,191
– –
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$47M 2.28%
5,653,029
– –
VTAE
15
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$43.5M 2.11%
2,613,199
– –
TRVN
16
DELISTED
Trevena, Inc.
TRVN
$28.8M 1.4%
7,699
+1,600
+26% +$5.3M
CRCM
17
DELISTED
CARE.COM, INC.
CRCM
$27M 1.31%
3,260,989
– –
WIFI
18
DELISTED
Boingo Wireless, Inc.
WIFI
$26.5M 1.29%
3,459,460
-1,008,500
-23% -$7.49M
HIVE
19
DELISTED
Aerohive Networks
HIVE
$23.3M 1.13%
4,861,455
– –
OREX
20
DELISTED
Orexigen Therapeutics, Inc.
OREX
$22.5M 1.09%
370,900
– –
LOXO
21
DELISTED
Loxo Oncology, Inc
LOXO
$21.1M 1.02%
+1,792,207
New +$20.9M
LXRX icon
22
Lexicon Pharmaceuticals
LXRX
$1.03B
$15.2M 0.74%
2,382,286
+714,286
+43% +$5.76M
ROKA
23
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$14.2M 0.69%
322,043
– –
MM
24
DELISTED
MILLENNIAL MEDIA INC COM STK (DE)
MM
$13.2M 0.64%
8,224,752
– –
ECOM
25
DELISTED
CHANNELADVISOR CORPORATION
ECOM
$12M 0.58%
556,692
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q4 2014 Portfolio in Review

As of Q4 2014, NEA Management Company held 37 positions worth $2.06B, up 4.8% from $1.97B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

NEA Management Company withdrew a net $114M in Q4 2014, closing 2 positions and reducing 5 holdings. Its most notable exit was Nektar Therapeutics, an estimated $22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 48% a quarter earlier, followed by Communication Services and Technology.

Against the trend, NEA Management Company opened a new position in NEVRO CORP. worth $53M.

  • NEA Management Company's largest Q4 2014 buy was NEVRO CORP.: 1,369,899 shares worth $53M.
  • NEA Management Company added most to Lexicon Pharmaceuticals in Q4 2014, an estimated $5.76M increase.
  • NEA Management Company's biggest Q4 2014 reduction was Groupon, cutting an estimated $72.3M.
  • NEA Management Company fully exited Nektar Therapeutics in Q4 2014, selling an estimated $22M.
  • NEA Management Company's ten largest holdings make up 75% of its $2.06B portfolio in Q4 2014.
  • NEA Management Company opened 2 new positions and closed 2 in Q4 2014.
  • NEA Management Company's portfolio value rose 4.8% quarter-over-quarter to $2.06B.

Based on NEA Management Company's 13F filing for Q4 2014, filed 26 Jan 2015.